1. Home
  2. FLC vs HUMA Comparison

FLC vs HUMA Comparison

Compare FLC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Total Return Fund Inc

FLC

Flaherty & Crumrine Total Return Fund Inc

SELL

Current Price

$15.45

Market Cap

162.4M

Sector

Finance

ML Signal

SELL

Logo Humacyte Inc.

HUMA

Humacyte Inc.

BUY

Current Price

$0.44

Market Cap

165.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FLC
HUMA
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.4M
165.7M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
FLC
HUMA
Price
$15.45
$0.44
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $1.63
AVG Volume (30 Days)
42.6K
★ 5.7M
Earning Date
01-01-0001
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.37
EPS
★ N/A
N/A
Revenue
N/A
★ $2,038,000.00
Revenue This Year
N/A
$72.32
Revenue Next Year
N/A
$518.79
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.33
$0.34
52 Week High
$18.09
$1.78

Technical Indicators

Market Signals
Indicator
FLC
HUMA
Relative Strength Index (RSI) 37.20 42.64
Support Level $15.33 $0.34
Resistance Level $15.85 $0.46
Average True Range (ATR) 0.20 0.04
MACD 0.02 0.01
Stochastic Oscillator 13.46 56.81

Price Performance

Historical Comparison
FLC
HUMA

About FLC Flaherty & Crumrine Total Return Fund Inc

Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: